+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-03-08Number of Pages: 184

Antiviral Drugs Market (Disease Indication - Hepatitis Virus Infection, HIV Infection, and Respiratory Virus Infection; Product Type - Branded Drugs and Generic Drugs; Distribution Channels - Hospital Pharmacy Store, Retail Pharmacy Store, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2024

Global Antiviral Drugs Market: Snapshot 

With the significant increase in the incidence of viral infections, the global antiviral drugs market is witnessing a substantial rise in its size and valuation. The increasing prevalence of chronic infections, such as HIV/AIDS and hepatitis B, which require long-term treatment, is also adding considerably to the growth of this market. 

Going forward, the strong focus of drugmakers on research and developments, resulting in innovation and advancements in drugs and therapies, together with the rising reports of newer viral infectious diseases, is likely to boost the market for antiviral drugs to great extents over the forthcoming years. The availability of low cost treatments and the advancements in healthcare facilities in developing regions are also projected to impact this market positively in the near future. 

The opportunity in the global market for antiviral drugs was worth US$48.3 bn in 2015. Researchers anticipate it to increase to US$82.9 bn by 2024, rising at a CAGR of 6.40% between 2016 and 2024. 

antiviral drugs market

North America to Continue as Market Leader 

Among all the regional markets for antiviral drugs, namely, Asia pacific, North America, Latin America, the Middle East and Africa, and Europe, the leading position has been acquired by North America. With a share of more than 50%, the North America market for antiviral drugs stood strong in 2015 and is expected to remain dominant over the next few years. The increasing pool of patients suffering from viral infections and the high cost of new drugs are likely to boost this regional market remarkably over the years to come. 

Europe stood second in the global market for antiviral drugs in 2015. Analysts predict this regional market will retain its position in the coming years, thanks to the large number of patients undergoing antiretroviral treatments, fueled by the increasing preference for novel drugs among consumers. The rising level of awareness, better diagnostic facilities, continued launches of effective drugs, and the presence of favorable reimbursement policies for the high-cost treatments are also expected to drive the Europe market for antiviral drugs over the next few years. 

Among other regional antiviral drugs markets, Asia Pacific, followed by the Middle East and Africa, is anticipated to present most promising opportunities for the growth of this market. The key factors attributed for this are the soaring prevalence of HIV/AIDS and hepatitis, high-paced spreading of various infectious viral diseases, such as influenza, and the increasing preference for better healthcare facilities. The rising penetration of drugs for novel viral infections, such as Ebola and Zika, together with improved as well as affordable second version drugs, is anticipated to drive both the markets, i.e., Asia Pacific and the Middle East and Africa, over the forthcoming years. 

Demand for Antiviral Drugs to Remain High from HIV Infection Segment 

Antiviral drugs are mainly utilized in the treatment of hepatitis virus infection, HIV infection, and respiratory virus infection. With the alarming rise in the reports of HIV infection, the demand for antiviral drugs from this segment has been higher than others. Thanks to the invention of new drugs for HIV, which convert fatal illness into chronic pathology thereby increasing the lifespan of the patient, favorable reimbursement policies, and the availability of affordable drugs in emerging countries, the segment is likely to remain driving high demand for these drugs over the years to come. 

Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline Plc, Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Cipla Inc., Bristol-Myers Squibb Co., and AbbVie Inc. are some of the leading antiviral drug makers across the world.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights
2. Assumptions and Research Methodology

3. Executive Summary: Global Antiviral Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Disease Indication Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. Global Antiviral Drugs Market Analysis and Forecasts, 2014–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s Five Force Analysis
     4.7. Market Outlook
     4.8. Antiviral Drugs: FDA Approvals and Patent Expiries by each drug class 
     4.9. Global relative prevalence rate of each hepatitis genotype infection
     4.10. Global relative prevalence rate of HIV infection
     4.11. Pipeline Analysis: Major Market Players

5. Global Antiviral Drugs Market Analysis and Forecasts, By Disease Indication 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Forecast by Disease Indication, 2014–2024
            5.4.1. Hepatitis Virus Infection
            5.4.2. HIV Infection
            5.4.3. Respiratory Virus Infection
            5.4.4. Others
     5.5. Market Attractiveness by Disease Indication 

6. Global Antiviral Drugs Market Analysis and Forecasts, by Product Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Forecast by Product Type, 2014–2024
            6.4.1. Branded Drugs
            6.4.2. Generic Drugs
     6.5. Market Attractiveness by Product Type 

7. Global Antiviral Drugs Market Analysis and Forecasts, by Distribution Channels 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Forecast by Distribution Channels, 2014–2024
            7.4.1. Hospital Pharmacy Store
            7.4.2. Retail Pharmacy Store
            7.4.3. Online Pharmacy
     7.5. Market Attractiveness by Distribution Channels 

8. Global Antiviral Drugs Market Analysis and Forecasts, by Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value Forecast by Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Latin America 
            8.3.5. Middle East and Africa 
     8.4. Market Attractiveness by Country/Region

9. North America Antiviral Drugs Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
            9.1.3. Key Trends
     9.2. Market Value Forecast by Disease Indication, 2014–2024
            9.2.1. Hepatitis Virus Infection
            9.2.2. HIV Infection
            9.2.3. Respiratory Virus Infection
            9.2.4. Others
     9.3. Market Value Forecast by Product Type, 2014–2024
            9.3.1. Branded Drugs
            9.3.2. Generic Drugs
     9.4. Market Value Forecast by Distribution Channels, 2014–2024
            9.4.1. Hospital Pharmacy Store
            9.4.2. Retail Pharmacy Store
            9.4.3. Online Pharmacy
     9.5. Market Value Forecast by Country, 2014–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Disease Indication 
            9.6.2. By Product Type 
            9.6.3. By Distribution Channels 
            9.6.4. By Country

10. Europe Antiviral Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
            10.1.3. Key Trends
     10.2. Market Value Forecast by Disease Indication, 2014–2024
            10.2.1. Hepatitis Virus Infection
            10.2.2. HIV Infection
            10.2.3. Respiratory Virus Infection
            10.2.4. Others
     10.3. Market Value Forecast by Product Type, 2014–2024
            10.3.1. Branded Drugs
            10.3.2. Generic Drugs
     10.4. Market Value Forecast by Distribution Channels, 2014–2024
            10.4.1. Hospital Pharmacy Store
            10.4.2. Retail Pharmacy Store
            10.4.3. Online Pharmacy
     10.5. Market Value Forecast by Country, 2014–2024
            10.5.1. U.K.
            10.5.2. Germany
            10.5.3. France
            10.5.4. Italy
            10.5.5. Spain
            10.5.6. Russia
            10.5.7. Rest of Europe
     10.6. Market Attractiveness Analysis 
            10.6.1. By Disease Indication 
            10.6.2. By Product Type 
            10.6.3. By Distribution Channels 
            10.6.4. By Country

11. Asia Pacific Antiviral Drugs Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
            11.1.3. Key Trends
     11.2. Market Value Forecast by Disease Indication, 2014–2024
            11.2.1. Hepatitis Virus Infection
            11.2.2. HIV Infection
            11.2.3. Respiratory Virus Infection
            11.2.4. Others
     11.3. Market Value Forecast by Product Type, 2014–2024
            11.3.1. Branded Drugs
            11.3.2. Generic Drugs
     11.4. Market Value Forecast by Distribution Channels, 2014–2024
            11.4.1. Hospital Pharmacy Store
            11.4.2. Retail Pharmacy Store
            11.4.3. Online Pharmacy
     11.5. Market Value Forecast by Country, 2014–2024
            11.5.1. India
            11.5.2. China
            11.5.3. Japan
            11.5.4. Australia & New Zealand
            11.5.5. Rest of Asia Pacific
     11.6. Market Attractiveness Analysis 
            11.6.1. By Disease Indication 
            11.6.2. By Product Type 
            11.6.3. By Distribution Channels 
            11.6.4. By Country

12. Latin America Antiviral Drugs Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
            12.1.3. Key Trends
     12.2. Market Value Forecast by Disease Indication, 2014–2024
            12.2.1. Hepatitis Virus Infection
            12.2.2. HIV Infection
            12.2.3. Respiratory Virus Infection
            12.2.4. Others
     12.3. Market Value Forecast by Product Type, 2014–2024
            12.3.1. Branded Drugs
            12.3.2. Generic Drugs
     12.4. Market Value Forecast by Distribution Channels, 2014–2024
            12.4.1. Hospital Pharmacy Store
            12.4.2. Retail Pharmacy Store
            12.4.3. Online Pharmacy
     12.5. Market Value Forecast by Country, 2014–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6. Market Attractiveness Analysis 
            12.6.1. By Disease Indication 
            12.6.2. By Product Type 
            12.6.3. By Distribution Channels 
            12.6.4. By Country

13. Middle East and Africa Antiviral Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
            13.1.3. Key Trends
     13.2. Market Value Forecast by Disease Indication, 2014–2024
            13.2.1. Hepatitis Virus Infection
            13.2.2. HIV Infection
            13.2.3. Respiratory Virus Infection
            13.2.4. Others
     13.3. Market Value Forecast by Product Type, 2014–2024
            13.3.1. Branded Drugs
            13.3.2. Generic Drugs
     13.4. Market Value Forecast by Distribution Channels, 2014–2024
            13.4.1. Hospital Pharmacy Store
            13.4.2. Retail Pharmacy Store
            13.4.3. Online Pharmacy
     13.5. Market Value Forecast by Country, 2014–2024
            13.5.1. South Africa
            13.5.2. GCC Countries
            13.5.3. Rest of Middle East and Africa
     13.6. Market Attractiveness Analysis 
            13.6.1. By Disease Indication 
            13.6.2. By Product Type 
            13.6.3. By Distribution Channels 
            13.6.4. By Country

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis by Company – 2016 (Estimated)
     14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. AbbVie, Inc. 
                      14.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.1.2 Financial Overview
                      14.3.1.3 Product Portfolio
                      14.3.1.4 SWOT Analysis
                      14.3.1.5 Strategic Overview
            14.3.2. Bristol-Myers Squibb Company 
                      14.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.2.2 Financial Overview
                      14.3.2.3 Product Portfolio
                      14.3.2.4 SWOT Analysis
                      14.3.2.5 Strategic Overview
            14.3.3. Cipla, Inc. 
                      14.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.3.2 Financial Overview
                      14.3.3.3 Product Portfolio
                      14.3.3.4 SWOT Analysis
                      14.3.3.5 Strategic Overview
            14.3.4. F. Hoffmann-La Roche Ltd. 
                      14.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.4.2 Financial Overview
                      14.3.4.3 Product Portfolio
                      14.3.4.4 SWOT Analysis
                      14.3.4.5 Strategic Overview
            14.3.5. Gilead Sciences, Inc. 
                      14.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.5.2 Financial Overview
                      14.3.5.3 Product Portfolio
                      14.3.5.4 SWOT Analysis
                      14.3.5.5 Strategic Overview
            14.3.6. GlaxoSmithKline plc.
                      14.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.6.2 Financial Overview
                      14.3.6.3 Product Portfolio
                      14.3.6.4 SWOT Analysis
                      14.3.6.5 Strategic Overview
            14.3.7. Johnson & Johnson 
                      14.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.7.2 Financial Overview
                      14.3.7.3 Product Portfolio
                      14.3.7.4 SWOT Analysis
                      14.3.7.5 Strategic Overview
            14.3.8. Merck & Co., Inc. 
                      14.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.8.2 Financial Overview
                      14.3.8.3 Product Portfolio
                      14.3.8.4 SWOT Analysis
                      14.3.8.5 Strategic Overview
            14.3.9. Mylan N.V. 
                      14.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.9.2 Financial Overview
                      14.3.9.3 Product Portfolio
                      14.3.9.4 SWOT Analysis
                      14.3.9.5 Strategic Overview
            14.3.10. Teva Pharmaceutical Industries Ltd. 
                      14.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
                      14.3.10.2 Financial Overview
                      14.3.10.3 Product Portfolio
                      14.3.10.4 SWOT Analysis
                      14.3.10.5 Strategic Overview
            14.3.11. Others

List of Figures

Figure 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 02: FDA Approvals
Figure 03: FDA Approvals
Figure 04: FDA Approvals
Figure 05: FDA Approvals
Figure 06: FDA Approvals
Figure 07: FDA Approvals
Figure 08: FDA Approvals
Figure 09: FDA Approvals
Figure 10: HIV Prevalence
Figure 11: Hepatitis c virus prevalence
Figure 12: Pipeline Analysis
Figure 13: Global Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 14: Global Hepatitis Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 15: Global HIV Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 16: Global Respiratory Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 17: Global Other Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 18: Antiviral Drugs Market Attractiveness Analysis, Disease Indication, 2016–2024
Figure 19: Global Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 20: Global Branded Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 21: Global Generic Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 22: Antiviral Drugs Market Attractiveness Analysis, by Product, 2016–2024 
Figure 23: Global Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 24: Global Hospital Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 25: Global Retail Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 26: Global Online Pharmacy Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 27: Antiviral Drugs Market Attractiveness Analysis, by Distribution Channels, 2016–2024
Figure 28: Global Antiviral Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 29: Antiviral Drugs Market Attractiveness Analysis, by Region, 2016–2024
Figure 30: North America Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 31: North America Market Attractiveness Analysis, by Country, 2016–2024
Figure 32: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 33: North America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 34: North America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 35: North America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 36: North America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 37: North America Market Attractiveness Analysis, by Product, 2016-2024
Figure 38: North America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 39: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 40: Europe Market Attractiveness Analysis, by Country/ Region, 2016–2024
Figure 41: Europe Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 42: Europe Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 43: Europe Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 44: Europe Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 45: Europe Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 46: Europe Market Attractiveness Analysis, by Product, 2016-2024
Figure 47: Europe Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 48: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 49: Asia Pacific Market Attractiveness Analysis, by Country/Region, 2016–2024
Figure 50: Asia Pacific Market Value Share Analysis, by Country/ Region, 2016 and 2024
Figure 51: Asia Pacific Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 52: Asia Pacific Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 53: Asia Pacific Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 54: Asia Pacific Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 55: Asia Pacific Market Attractiveness Analysis, by Product, 2016-2024
Figure 56: Asia Pacific Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 57: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 58: Latin America Market Attractiveness Analysis, by Country/Region, 2016–2024
Figure 59: Latin America Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 60: Latin America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 61: Latin America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 62: Latin America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 63: Latin America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 64: Latin America Market Attractiveness Analysis, by Product, 2016-2024
Figure 65: Latin America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 66: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 67: MEA Market Attractiveness Analysis, by Country/ Region, 2016-2024
Figure 68: MEA Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 69: Middle East & Africa Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 70: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 71: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 72: Middle East & Africa Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 73: Middle East & Africa Market Attractiveness Analysis, by Product, 2016-2024
Figure 74: Middle East & Africa Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 75: Global Antiviral Drugs Market Share Analysis, by Company, (2015)

List of Tables

Table 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 02: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 03: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 04: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 05: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 06: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 07: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 08: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 09: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024
Table 10: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 11: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 12: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 13: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 2014–2024
Table 14: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 15: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 16: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 17: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024
Table 18: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 19: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 20: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 21: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 2014–2024
Table 22: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 23: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 24: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024

Global Antiviral Drugs Market: Overview 

In past 30 years, significant progress is seen in antiviral drugs market, mainly in case of the drugs that target the entry and escaping mechanisms of viruses, with an aim of improving the quality of patient’s life by introducing broad spectrum of combination therapy drugs. Viruses rely on host’s machinery for replication as well as metabolic activities, thus antiviral agents target these mechanisms by several inhibitor classes such as Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Fusion Inhibitors (FIs), Entry Inhibitors - CCR5 co-receptor antagonist, Protease Inhibitors (PIs), HIV Integrase strand transfer inhibitors, among others. 

Demand for new and improved targeted therapies for viral diseases continues to rise, primarily due to invention of broad spectrum antiviral drugs. Introduction of combinational drug therapies with improved pharmacokinetic and pharmacodynamics properties, and focus on emerging regions for market penetration by creating awareness along with availability of affordable drugs are major opportunities for the global antiviral drugs market. 

The market overview section of the report comprises qualitative analysis of the overall antiviral drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the disease indications, product type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The prevalence HIV infection and HCV infection has also been provided, along with the FDA approvals and patent expiries of major drugs by each drug class. The pipeline analysis of major market players has been given in the market overview section. 

Global Antiviral Drugs Market: Segmentation 

The global antiviral drugs market has been segmented on the basis of disease indication, product type, and distribution channels. On the basis of disease indication, the global antiviral drugs market is categorized as hepatitis virus infection, HIV infection, Respiratory virus infection, and others. In terms of product type, the global antiviral drugs market is divided into branded drugs, and generic drugs. Furthermore, on the basis of distribution channels, the global antiviral drugs market has been classified as hospital pharmacy store, retail pharmacy store, and online pharmacy.

The market for these disease indication, product type, and distribution channels has been extensively analyzed on the basis of factors such as drug usage pattern, sales revenue, geographic presence and technological developments. The market size and forecast in terms of revenue (USD million) for each of these segments have been provided for the period 2014 to 2024, considering 2015 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2016 to 2024. 

Geographically, the antiviral drugs market has been classified into five segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2014 to 2024, in terms of disease indication, product type, and distribution channels, along with the CAGR (%) for the forecast period 2016 to 2024. 

Global Antiviral Drugs Market: Competitive Analysis 

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global antiviral drugs market, in terms of percentage share in 2016 (estimated) has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. 

The report concludes with the profiles of major players in the global antiviral drugs market such as AbbVie, Inc., Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Mylan N.V., GlaxoSmithKline plc. Johnson & Johnson, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments. 

The global antiviral drugs market is segmented as follows: 

By Disease Indication

  • Hepatitis Virus Infection
  • HIV Infection
  • Respiratory Virus Infection
  • Others 

By Product Type

  • Branded Drugs
  • Generic Drugs 

By Distribution Channels

  • Hospital Pharmacy Store
  • Retail Pharmacy Store
  • Online Pharmacy 

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa 


 
 
Back To Top